141 related articles for article (PubMed ID: 37888870)
1. The comparison of safety and cost between reference drug of rituximab and its biosimilar Riximyo in lymphoproliferative disorders and other hematological diseases. Single center experience.
Olszewska-Szopa M; Ożańska A; Ożański T; Rybka J; Wróbel T
Leuk Lymphoma; 2024 Jan; 65(1):55-61. PubMed ID: 37888870
[TBL] [Abstract][Full Text] [Related]
2. Comparison of outcomes using the rituximab originator MabThera with the biosimilar Truxima in patients with ANCA-associated vasculitis.
Antonelou M; Abro A; Heath R; Iacovou A; Ashley C; Caplan J; Morgan MD; Logan S; Harper L; Salama AD
Scand J Rheumatol; 2022 Mar; 51(2):135-141. PubMed ID: 34474634
[TBL] [Abstract][Full Text] [Related]
3. Factors Influencing Infusion-Related Reactions Following Dosing of Reference Rituximab and PF-05280586, a Rituximab Biosimilar.
Courville J; Nastoupil L; Kaila N; Kelton J; Zhang J; Alcasid A; Nava-Parada P
BioDrugs; 2021 Jul; 35(4):459-468. PubMed ID: 34152584
[TBL] [Abstract][Full Text] [Related]
4. Safety of switching between rituximab biosimilars in onco-hematology.
Urru SAM; Spila Alegiani S; Guella A; Traversa G; Campomori A
Sci Rep; 2021 Mar; 11(1):5956. PubMed ID: 33727667
[TBL] [Abstract][Full Text] [Related]
5. Interchangeability and adverse events in originator-rituximab and its biosimilar (CT-P10) among rheumatic patients: a real-life experience.
Bahap-Kara M; Duran E; Bayraktar-Ekincioglu A; Karadag O
Intern Emerg Med; 2023 Apr; 18(3):791-799. PubMed ID: 36826744
[TBL] [Abstract][Full Text] [Related]
6. Comparison of rituximab originator (MabThera
Perez T; Rico A; Boutière C; Maarouf A; Roudot M; Honoré S; Pelletier J; Bertault-Peres P; Audoin B
Mult Scler; 2021 Apr; 27(4):585-592. PubMed ID: 32180508
[TBL] [Abstract][Full Text] [Related]
7. Safety and tolerability of a 90-minute rapid infusion of Sandoz biosimilar rituximab in B-cell lymphoproliferative disorders in a real-world setting.
Muntañola A; Arguiñano-Pérez JM; Dávila J; de Villambrosia SG; Carpio C; Jiménez-Ubieto A; Salar A;
Clin Transl Sci; 2023 Feb; 16(2):305-312. PubMed ID: 36385738
[TBL] [Abstract][Full Text] [Related]
8. The in-use stability of the rituximab biosimilar Rixathon®/Riximyo® upon preparation for intravenous infusion.
Lamanna WC; Heller K; Schneider D; Guerrasio R; Hampl V; Fritsch C; Schiestl M
J Oncol Pharm Pract; 2019 Mar; 25(2):269-278. PubMed ID: 28950806
[TBL] [Abstract][Full Text] [Related]
9. The safety and clinical effectiveness of rapid infusion with CT-P10 in patients with non-Hodgkin's lymphoma or chronic lymphocytic leukemia: A retrospective non-interventional post-authorization safety study in Europe.
Bishton M; Marshall S; Harchowal J; Salles G; Golfier C; Tucci A; Fernández AR; Sanchez Blanco JJ; Bocchia M; Kim S; Lee YN; Zinzani PL
Hematol Oncol; 2022 Aug; 40(3):370-380. PubMed ID: 35168291
[TBL] [Abstract][Full Text] [Related]
10. Safety and effectiveness of biosimilar of Rituximab CT-P10 in the treatment of cryoglobulinemic vasculitis: the MARBLe study (Mixed cryoglobulinemiA Rituximab BiosimiLar).
Vacchi C; Visentini M; Gragnani L; Fraticelli P; Tavoni A; Filippini D; Saccardo F; Lauletta G; Colantuono S; Atzeni F; Pioltelli P; Manfredi A; Casato M; Zignego AL; Monti G; Pietrogrande M; Galli M; Sebastiani M
Intern Emerg Med; 2021 Jan; 16(1):149-156. PubMed ID: 32524338
[TBL] [Abstract][Full Text] [Related]
11. [Retrospective cohort study of rituximab biosimilar (Rixathon®) adverse events in adult hematology and pediatric nephrology].
Videau M; Cotteret C; Sibon D; Schlatter J
Rev Med Liege; 2020 Mar; 75(3):185-189. PubMed ID: 32157845
[TBL] [Abstract][Full Text] [Related]
12. Rapid infusion of infliximab biosimilars and the incidence and severity of infusion-related reactions in patients with inflammatory bowel disease.
Rusch C; Wood M; Kennedy AG; Tompkins BJ; Frasca JD
J Clin Pharm Ther; 2022 Nov; 47(11):1851-1857. PubMed ID: 36134561
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of two rituximab biosimilars for treating immune thrombocytopenia: a reference-product matched study.
Mageau A; Bonnotte B; Ebbo M; Dossier A; Galicier L; Souchaud-Debouverie O; Orvain C; Gerfaud-Valentin M; Gobert D; Riviere E; Audia S; Mahevas M; Michel M; Viallard JF; Godeau B
Platelets; 2023 Dec; 34(1):2200848. PubMed ID: 37128870
[TBL] [Abstract][Full Text] [Related]
14. A Randomized, Double-Blind, Efficacy and Safety Study of PF-05280586 (a Rituximab Biosimilar) Compared with Rituximab Reference Product (MabThera
Sharman JP; Liberati AM; Ishizawa K; Khan T; Robbins J; Alcasid A; Rosenberg JA; Aurer I
BioDrugs; 2020 Apr; 34(2):171-181. PubMed ID: 31820339
[TBL] [Abstract][Full Text] [Related]
15. Biosimilar monoclonal antibodies in lymphoma: a critical appraisal.
Rioufol C; Salles G
Expert Rev Anticancer Ther; 2015 May; 15(5):569-78. PubMed ID: 25818308
[TBL] [Abstract][Full Text] [Related]
16. Brief Report: Safety and Immunogenicity of Rituximab Biosimilar GP 2013 After Switch From Reference Rituximab in Patients With Active Rheumatoid Arthritis.
Tony HP; Krüger K; Cohen SB; Schulze-Koops H; Kivitz AJ; Jeka S; Vereckei E; Cen L; Kring L; Kollins D
Arthritis Care Res (Hoboken); 2019 Jan; 71(1):88-94. PubMed ID: 30295429
[TBL] [Abstract][Full Text] [Related]
17. CT-P10 (Truxima™): A Rituximab Biosimilar.
Deeks ED
BioDrugs; 2017 Jun; 31(3):275-278. PubMed ID: 28497220
[TBL] [Abstract][Full Text] [Related]
18. Long-Term Real-World Post-approval Safety Data of Multiple Biosimilars from One Marketing-Authorization Holder After More than 18 Years Since Their First Biosimilar Launch.
Sagi S; Anjaneya P; Kalsekar S; Kottke A; Cohen HP
Drug Saf; 2023 Dec; 46(12):1391-1404. PubMed ID: 37902937
[TBL] [Abstract][Full Text] [Related]
19. Real-world use and acceptance of biosimilar monoclonal antibodies of rituximab in oncology practice in the USA.
Shelbaya A; Kelton JM; Thompson J; Alvir JM; Maculaitis MC; Yang J
Future Oncol; 2021 Oct; 17(30):3941-3950. PubMed ID: 34259584
[TBL] [Abstract][Full Text] [Related]
20. Humanized anti-CD20 monoclonal antibody (Rituximab) treatment for post-transplant lymphoproliferative disorder.
Ganne V; Siddiqi N; Kamaplath B; Chang CC; Cohen EP; Bresnahan BA; Hariharan S
Clin Transplant; 2003 Oct; 17(5):417-22. PubMed ID: 14703923
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
